Reforms are needed to make the US Food and Drug Administration’s (FDA) advisory committee process more consistent and transparent, according to three researchers from the Program on Regulation, ...
US regulators’ recent decision to scrap a little-used panel of arthritis experts is seen as an unwelcome signal that they don’t expect rapid new developments of novel therapies in rheumatology. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results